Hoogwegt agrees to buy the first production batch of Opalia's cell-cultivated whole milk
Dutch dairy group Hoogwegt will buy the first production batch of Opalia's cell-cultivated whole milk and test it in cheese, yoghurt and butter.
Hoogwegt, the Dutch dairy ingredients group, has agreed to buy the first production batch of cell-cultivated whole milk from Opalia, a Montreal company founded in 2020 by Jennifer Côté, co-founder and chief executive, and Lucas House, chief technology officer. Both companies describe the transaction as a world first for whole milk produced from bovine mammary cells. Volume and price are confidential. "At this stage, the purpose is to evaluate the technology, not to make a commercial margin," said Roland Wientjes, Hoogwegt's global technology director, who told Green Queen the price covers the cost of producing this batch.
Opalia grows bovine mammary cells in a bioreactor and induces lactation, so the output is milk with its full composition of proteins, fats and sugars rather than a single ingredient. That is the difference from precision fermentation, which typically targets one dairy protein at a time. The company works from an immortalised cell line, so it no longer needs to take tissue from animals, and it has removed fetal bovine serum from the process, which it treats as the precondition for cost parity with conventional dairy. The platform is patent pending and has so far been validated at laboratory scale only. The milk can be supplied to business customers as fluid or powdered whole milk, and Opalia says the same material can go into butter, cream, cheese and yoghurt.
Hoogwegt will analyse the composition first, then test functional properties in fresh cheese, yoghurt and butter, looking at both fully cell-based products and hybrid formulations. No product, market or launch date has been confirmed. The purchase follows Hoogwegt's investment in Opalia and a commercial agreement announced in August 2025 that covers 2026 and 2027. The batch changes hands at Fi Europe in Frankfurt, which runs from 17 to 19 November 2026, where the two companies will show a prototype on Hoogwegt's stand and look for development partners and offtake agreements. Côté and Wientjes will both be there.
Opalia closed the first tranche of a seed round in April 2026 at C$3.2 million, about US$2.3 million, led by Nàdarra Ventures, with Spring Capital, UCEED and Anges Québec taking part alongside existing backers Investissement Québec, Cycle Momentum and BoxOne Ventures. The money funds a modular bioreactor at the Montreal site designed for 28 litres a day, which the company describes as the output of one cow, inside a 24-month validation programme. Commercialisation is targeted for 2028, at a price Opalia puts at two US dollars a litre. A novel food pre-market notification to Health Canada is planned for the middle of 2027, with filings in Europe and Asia following the North American route. The company also reports a paid pilot with the Canadian arm of one of the world's largest dairy groups and letters of intent with companies in North America, Europe and Asia. "The future of dairy will be a mix of traditional and new production methods, and we want to help shape it," said Wientjes.
Why it matters for AgTech founders: the sums here are small enough to be invisible on either balance sheet, and the transaction is still worth studying, because this is the rung most deep tech food companies fall off. Three points. First, a sale at cost is not revenue, and at this stage it is worth more than revenue would be. It turns an existing investor into a named customer and gives the next round a buyer rather than a letter of intent. If you have a strategic on your cap table, the useful question is not whether they believe the technology, it is what the smallest thing is that you can ask them to pay for, and when. Second, read the capacity figure honestly. A bioreactor sized at the output of one cow, in 2026, with 2028 as the market date, is the real position of cellular dairy, and a supply deal with a large buyer does not move it. Founders who let a partner announcement imply scale spend the next year explaining the gap. Third, note the regulatory sequencing. Canada goes first, Europe and Asia follow, and the United States would need two agencies with at least one state already closed to cell-based dairy. Choosing the filing order by the shortest path rather than the largest market buys years, and it is a decision to take before the data package is written, not after.
Hoogwegt agrees to buy the first production batch of Opalia's cell-cultivated whole milk
The Dutch dairy ingredients group will test the milk in fresh cheese, yoghurt and butter. Opalia hands the batch over at Fi Europe in Frankfurt next month, with volume and price confidential.
Hoogwegt, the Dutch dairy ingredients group, has agreed to buy the first production batch of cell-cultivated whole milk from Opalia, a Montreal company founded in 2020 by Jennifer Côté, co-founder and chief executive, and Lucas House, chief technology officer. Both companies describe the transaction as a world first for whole milk produced from bovine mammary cells. Volume and price are confidential. "At this stage, the purpose is to evaluate the technology, not to make a commercial margin," said Roland Wientjes, Hoogwegt's global technology director, who told Green Queen the price covers the cost of producing this batch.
Opalia grows bovine mammary cells in a bioreactor and induces lactation, so the output is milk with its full composition of proteins, fats and sugars rather than a single ingredient. That is the difference from precision fermentation, which typically targets one dairy protein at a time. The company works from an immortalised cell line, so it no longer needs to take tissue from animals, and it has removed fetal bovine serum from the process, which it treats as the precondition for cost parity with conventional dairy. The platform is patent pending and has so far been validated at laboratory scale only. The milk can be supplied to business customers as fluid or powdered whole milk, and Opalia says the same material can go into butter, cream, cheese and yoghurt.
Hoogwegt will analyse the composition first, then test functional properties in fresh cheese, yoghurt and butter, looking at both fully cell-based products and hybrid formulations. No product, market or launch date has been confirmed. The purchase follows Hoogwegt's investment in Opalia and a commercial agreement announced in August 2025 that covers 2026 and 2027. The batch changes hands at Fi Europe in Frankfurt, which runs from 17 to 19 November 2026, where the two companies will show a prototype on Hoogwegt's stand and look for development partners and offtake agreements. Côté and Wientjes will both be there.
Opalia closed the first tranche of a seed round in April 2026 at C$3.2 million, about US$2.3 million, led by Nàdarra Ventures, with Spring Capital, UCEED and Anges Québec taking part alongside existing backers Investissement Québec, Cycle Momentum and BoxOne Ventures. The money funds a modular bioreactor at the Montreal site designed for 28 litres a day, which the company describes as the output of one cow, inside a 24-month validation programme. Commercialisation is targeted for 2028, at a price Opalia puts at two US dollars a litre. A novel food pre-market notification to Health Canada is planned for the middle of 2027, with filings in Europe and Asia following the North American route. The company also reports a paid pilot with the Canadian arm of one of the world's largest dairy groups and letters of intent with companies in North America, Europe and Asia. "The future of dairy will be a mix of traditional and new production methods, and we want to help shape it," said Wientjes.
Why it matters for AgTech founders: the sums here are small enough to be invisible on either balance sheet, and the transaction is still worth studying, because this is the rung most deep tech food companies fall off. Three points. First, a sale at cost is not revenue, and at this stage it is worth more than revenue would be. It turns an existing investor into a named customer and gives the next round a buyer rather than a letter of intent. If you have a strategic on your cap table, the useful question is not whether they believe the technology, it is what the smallest thing is that you can ask them to pay for, and when. Second, read the capacity figure honestly. A bioreactor sized at the output of one cow, in 2026, with 2028 as the market date, is the real position of cellular dairy, and a supply deal with a large buyer does not move it. Founders who let a partner announcement imply scale spend the next year explaining the gap. Third, note the regulatory sequencing. Canada goes first, Europe and Asia follow, and the United States would need two agencies with at least one state already closed to cell-based dairy. Choosing the filing order by the shortest path rather than the largest market buys years, and it is a decision to take before the data package is written, not after.
